武汉佰乐博代理：Research Grade Sabatolimab
货号：DHJ28402
产品链接：http://www.atagenix.com/product_detail-75240.html
免费热线：027-65279366 /18108604356
QQ：2663991332
咨询邮箱：products@biolabreagent.com
选购商城：https://www.antibodysystem.com
微信公众平台：佰乐博生物Biolab Reagents
产品介绍：Sabatolimab (MBG453)是一种高亲和力的人源化IgG4 (S228P)抗体，靶向TIM-3，一种调节适应性和先天免疫反应的抑制性受体。Sabatolimab是一种潜在的免疫抑制活性分子，可以靶向免疫细胞和骨髓细胞上的TIM-3。
通用名：Sabatolimab
纯度：>95% by SDS-PAGE.
浓度：1mg/ml
Formulationicon：0.01M PBS, pH 7.4.
内毒素：Please contact with the lab for this information.
别名：MBG-453
靶点;物种：Human CD366/HAVCR2/TIM-3
种类：Humanized
受体鉴定：IgG4-kappa
CAS: 2252262-24-9
存储条件：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
参考文献：
Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors. PMID: 33883177
Advances in myelodysplastic syndrome. PMID: 34474438
Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor. PMID: 36196369
Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes. PMID: 35883692
Updates on the Management of Acute Myeloid Leukemia. PMID: 36230677
Sabatolimab (MBG453) model-informed drug development for dose selection in patients with myelodysplastic syndrome/acute myeloid leukemia and solid tumors. PMID: 37186155
New Frontiers in Monoclonal Antibodies for the Targeted Therapy of Acute Myeloid Leukemia and Myelodysplastic Syndromes. PMID: 35886899
STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2. PMID: 37083373
TIM-3: a tumor-associated antigen beyond checkpoint inhibition? PMID: 36406467
Correction to: Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor. PMID: 36819977
[Management of AML in the elderly]. PMID: 36870810
New Checkpoint Inhibitors on the Road: Targeting TIM-3 in Solid Tumors. PMID: 35218498
EXABS-120-MDS Treatment of Higher Risk MDS. PMID: 36163758
EXABS-140-MDS Immune Therapy Approaches in MDS. PMID: 36164227
Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon? PMID: 33762100
Advances in myelodysplastic syndromes: promising novel agents and combination strategies. PMID: 36620919
Current status of phase 3 clinical trials in high-risk myelodysplastic syndromes: pitfalls and recommendations. PMID: 36215988
Biological therapy in elderly patients with acute myeloid leukemia. PMID: 36715330
Modulation of the Gal-9/TIM-3 Immune Checkpoint with α-Lactose. Does Anomery of Lactose Matter? PMID: 34944985
